CoChat
Sign Up
Cited by 215Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and ApplicationsPeptidase Inhibition and Analysis

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety

Ballal, Sanjana, Yadav, Madhav Prasad, Bal, Chandrasekhar, Sahoo, Ranjit Kumar, Tripathi, Madhavi·2020·European Journal of Nuclear Medicine and Molecular Imaging
DOI 10.1007/s00259-019-04567-2
Open this paper in CoChat — free account

Abstract

Purpose The objective of this study was to investigate and present the early results on the efficacy, safety, and quality of life of 225 Ac-DOTATATE targeted alpha therapy (TAT) in patients with advanced, progressive, 177 Lu-DOTATATE refractory, and somatostatin receptor (SSTR) expressing metastatic GEP-NETs.Methods In this prospective study, we recruited patients with metastatic GEP-NETs who were stable or progressive disease on 177 Lu-DOTATATE therapy. Systemic TAT using 225 Ac-DOTATATE was performed in all the patients with 225 Ac-DOTATATE (100 kBq/kg body weight) at an interval of 8 weeks. The primary end point was to assess the objective response (measured by RECIST 1.1 and functional M.D. Anderson criteria). The secondary end points included biochemical response assessment as per the Italian Trials in Medical Oncology (ITMO), adverse event profile as per CTCAE v5.0, and clinical response assessment by the quality of life (assessed with EORTC QLQ-GI.NET21 patient-based questionnaire).Results Between April 2018 and March 2019, 32 patients (17 females, 15 males, mean age 52 ± 9.2 years, 35-72 years) with either stable disease after completing 177 Lu-DOTATATE therapy (14, 44%) or progressive disease on 177 Lu-DOTATATE therapy (18, 56%) were included in the study. The morphological response was assessed in 24/32 patients that revealed partial remission in 15 and stable disease in 9. There was no documented disease progression or deaths in the median follow-up of 8 months (range 2-13 months). There was a significant decrease in the plasma chromogranin level post-225 Ac-DOTATATE therapy (P < 0.0001).Conclusion Our short-term clinical results indicate 225 Ac-DOTATATE TAT as a promising treatment option which adds a new dimension in patients who are refractory to 177 Lu-DOTATATE therapy or have reached the maximum prescribed cycles of 177 Lu-DOTATATE therapy.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00259-019-04567-2

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 23 references

Research works printed but not linked: 1

  1. Fayers PM, Aaronson NK, Bjordal K. On behalf of the EORTC Quality of Life Group et al. The EORTC QLQ-C30 scoring manual (3rd edition) Brussels: European Organisation for Research and Treatment of Cancer; 2001.

Cited by

Sorted by citations

See all 215

Related

Metadata

Authors
Ballal, S., Yadav, M. P., Bal, C., Sahoo, R. K., & Tripathi, M.
Affiliations
  • All India Institute of Medical Sciences (IN)
  • DR. B.R.A. Institute Rotary Cancer Hospital (IN)
Corresponding author
Bal, Chandrasekhar
ORCID
Venue
European Journal of Nuclear Medicine and Molecular Imaging
Publisher
Springer Science and Business Media LLC
Published
2019-11-10
Volume
47
Issue
4
Pages
934-946
ISSN
  • 1619-7070 (ISSN-L)
  • 1619-7089
DOI
10.1007/s00259-019-04567-2
OpenAlex
W2984721232
Cited by
215
References
23
Citations by year
2026: 24 · 2025: 42 · 2024: 31 · 2023: 34 · 2022: 36 · 2021: 34 · 2020: 14
FWCI
15.98
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
Keywords
targeted alpha therapy, gastroenteropancreatic neuroendocrine tumors, 177Lu-DOTATATE, peptide receptor radionuclide therapy, somatostatin receptors, refractory disease, progressive disease, objective response, quality of life, chromogranin A, treatment safety, adverse events, metastatic neuroendocrine tumors
MeSH terms
Adult, Aged, Female, Humans, Intestinal Neoplasms, Male, Middle Aged, Organometallic Compounds, Pancreatic Neoplasms, Prospective Studies, Quality of Life, Stomach Neoplasms, Octreotide, Neuroendocrine Tumors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review